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The indirect impact of the coronavirus disease 2019 (COVID-19) pandemic on cancer 
outcomes is of increasing concern. However, it is unclear the extent to which key treatment 
modalities have been affected. This population-based study aimed to assess the impact of the 
pandemic on radiotherapy activity in England. 
 
Methods: 
Data relating to all radiotherapy delivered for cancer in the English NHS, between February 
4th 2019 and June 28th 2020 was extracted from the National Radiotherapy Dataset (RTDS). 
Changes in average-weekly radiotherapy courses, attendances (reflecting fractions) and 
fractionation patterns following UK lockdown were compared to equivalent months in 2019 
overall, for specific diagnoses and across age groups. The significance of changes at 
lockdown was examined using interrupted time-series (ITS).  
 
Results: 
Average weekly radiotherapy courses fell by 19‧9% in April 2020, 6‧2% in May and 11‧6% 
in June. A relatively greater fall was observed for attendances (29‧1%, 31‧4% and 31‧5% in 
April, May and June respectively). These changes were significant on ITS (p<0.0001). The 
largest reduction in treatment courses was seen for patients aged ≥70 years (34‧4% vs. 7.3% 
in April) and for prostate and non-melanomatous skin (up to 77‧0% and 72‧4% respectively) 
cancers. Conversely, radiotherapy courses increased by up to 71‧3% in oesophageal, 143‧3% 
in bladder, and 36‧3% in rectal cancer. Increased use of ultra-hypofractionated breast 
radiotherapy (0‧2% to 60‧0% of courses; ITS p<0.0001)) substantially contributed to the 
observed reduction in attendances.  
 
Conclusions: 
Radiotherapy activity fell significantly whilst use of hypofractionated regimens rapidly 
increased in the English NHS during the first peak of the COVID-19 pandemic. An increase 
in treatments for some cancers suggests that radiotherapy compensated for reduced surgical 
activity. These data will assist healthcare providers in understanding the indirect 
consequences of the pandemic and the role of radiotherapy services in minimising these. 
 
Funding: No project specific funding was used.
3 
 
RESEARCH IN CONTEXT 
Evidence before this study 
The indirect consequences of the COVID-19 pandemic on the care of patients with cancer are 
of concern. However, the extent to which radiotherapy services were affected is unclear. To 
identify studies reporting on changes in radiotherapy activity during the COVID-19 
pandemic, we searched PubMed for articles published in English between 1st January 2020 to 
1st October 2020 using the search terms (“cancer” or “malignancy”) AND (“radiation 
therapy” OR “radiotherapy”) AND (“COVID-19” OR “coronavirus” OR “SARS-CoV-2”). 
To date only analyses of radiotherapy activity across single or small numbers of centres, or 
larger survey-based studies assessing changes to radiotherapy practice have been undertaken. 
These are at risk of responder bias and are not sufficiently comprehensive to detail changes in 
radiotherapy activity or prescriptions for individual cancers, nor to quantify how these have 
varied as the pandemic has progressed.   
 
Added value of this study 
To our knowledge, this is the first comprehensive, nationwide analysis of radiotherapy 
activity during the first wave of the COVID-19 pandemic. We demonstrate an overall fall in 
radiotherapy activity in the English NHS over this period. This is predominantly attributable 
to a reduction in treatments for prostate and non-melanomatous skin cancer; malignancies for 
which there is evidence for the safety of treatment delay. In contrast, treatments for 
oesophageal, bladder and rectal cancers have markedly increased. We also demonstrate a 
dramatic increase in the use of hypo-fractionated regimens. Radiotherapy activity remained 
suppressed in to June 2020 which may reflect delays in cancer diagnostic pathways. 
 
Implications of all the available evidence 
Whilst radiotherapy activity fell during the first wave of the pandemic, these data suggest that 
the overall impact of this is likely to be modest. In addition, radiotherapy appears to have 
mitigated against some of the indirect harms of the pandemic by maintaining curative 
treatment options despite the challenges facing surgical services. As COVID-19 infections 
again rise, these data are critical for modelling indirect harms of the pandemic and establish a 
new baseline for radiotherapy treatments from which to plan for the ongoing delivery of care 
throughout subsequent pandemic waves and into the recovery beyond. They also reinforce 





The indirect consequences of the coronavirus disease 2019 (COVID-19) pandemic are of 
increasing concern. The United Kingdom (UK) was one of the most severely affected 
countries in Europe during the first wave of COVID-19. As cases escalated in March 2020, 
the National Health Service (NHS) restructured in anticipation of large numbers of inpatients 
requiring respiratory support.(1)  Similar steps were taken by healthcare providers globally.(2)  
 
The impact of this pivot towards COVID-19 for patients with cancer is of particular concern 
given their need for timely diagnosis, treatment and symptom palliation. Alongside surgery 
and systemic anti-cancer therapy, radiotherapy plays a major role both as a curative treatment 
and in the palliation of localised symptoms from advanced disease. It is estimated that a third 
of all patients with cancer in the UK will receive radiotherapy during their disease course.(3) 
At the outset of the pandemic, all three modalities were affected by constraints on COVID-19 
testing and staff shortages. Surgical services faced additional pressure as a consequence of 
the adaptation of theatre space for the care of acutely unwell patients requiring ventilation.  
 
In response to these pressures, service providers, commissioners and professional bodies 
within the UK and internationally issued revised guidance for cancer care. Drawing on 
evidence and expert consensus these also addressed concerns about in hospital COVID-19 
transmission and the potentially heightened risk of cancer treatment in the midst of a 
pandemic.(4,5) Within these site-specific guidelines suggestions included treatment omission 
or delay, the use of radiotherapy to replace or to bridge to surgery, and the wider use of short, 
high daily dose (hypofractionated) radiotherapy.(5)   
 
As cases of COVID-19 rise again, it is important to understand the indirect consequences of 
the first pandemic peak. However, at present our understanding of changes to radiotherapy 
practise are limited to a small number of surveys of radiation oncology centres in Europe and 
the Americas.(6–8) These are at risk of responder bias, have limited information about 
individual cancers and regimen use, and are not able to quantify longitudinal changes during 
the pandemic. In the absence of this information, the indirect harms of the pandemic cannot 
be accurately modelled. Such data are also required by service providers, commissioners and 
clinicians to mitigate against these indirect consequences. This includes through identifying 
cohorts of patients for whom treatment has been modified and who as a consequence may 
require tailored clinical follow-up, and through establishing a new baseline for radiotherapy 
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treatment patterns from which planning for a second wave and for the longer-term recovery 
of cancer services can be developed. 
 
In England, all NHS radiotherapy providers submit data directly from their treatment delivery 
systems to Public Health England (PHE) on a monthly basis to form the National 
Radiotherapy Dataset (RTDS).(9) This contains information on greater than 135,000 courses 
of radiotherapy delivered across the English NHS each year. In this study, we used the RTDS 




This national population-based study analysed radiotherapy activity across all 52 English 
NHS radiotherapy providers over the year prior to the pandemic, during the first wave of 
cases from the date of the UK lockdown and through to the reduction of the UK’s COVID-19 
alert level in June 2020. PHE routinely collect data on the diagnosis and treatment of patients 
with cancer within the NHS under section 251 of the Health and Social Care act (2006). 
Study specific ethical approval was not sought for this work which was considered to be 
operational research within PHE’s core remit. 
 
Data: 
We extracted data for all external beam radiotherapy courses (episodes) and attendances 
(which closely align to fractions) delivered for cancer between 4th February 2019 – 28th June 
2020. All ages and tumour sites were included. There is limited radiotherapy capacity in 
England outside of these NHS centres. 
  
Data items from RTDS used within this analysis were: the diagnosis for which the treatment 
was delivered (defined using the International Classification of Disease (ICD) 10th edition)(10) 
allocated to clinically appropriate groupings (e.g. head and neck cancer) as detailed in 
Appendix page 1; patient age and sex; treatment intent (defined by the treating clinician 
(curative (including both primary/radical and adjuvant), palliative, other (including those 
where intent was not submitted)); planned dose in Gray (Gy); planned fractionation; date of 






Analysis of courses and attendance numbers: 
Radiotherapy courses were allocated to the week in which they started and attendances 
(fractions) to the week in which they occurred. Weeks were defined using International 
Organisation for Standardisation (ISO) calendar and allocated to the month in which they 
began. Radiotherapy activity was defined by the average (mean) weekly number of treatment 
courses and attendances per month. Percentage change in activity for each month between 
February and June 2020 was calculated compared to the equivalent month in 2019 (ordinarily 
limited year-on-year variation in activity is anticipated). This approach ensured minor weekly 
fluctuations were smoothed across each month and that comparisons recognised seasonality 
and bank holiday periods. During the study period between one and four providers per month 
had not submitted data at the time of data extraction (Appendix page 1). In order to adjust for 
this additional activity was incorporated based on the proportion of activity delivered by the 
missing centres in months where complete data were available. 
 
The differences in courses and attendances compared to 2019 were examined by provider, 
treatment intent, age, patient sex and individual diagnoses. Given the known increase in risk 
of adverse COVID-19 outcomes with age,(11) data were dichotomised at 70 years in line with 
UK shielding advice.(12)  
 
The statistical significance of the change in activity following lockdown was assessed using 
interrupted time-series (ITS) analysis with multi-variable generalised linear regression 
models.(13) The pandemic lockdown and recovery were specified as binary variables, applied 
to all time points beyond 23rd March 2020 (the date of lockdown) and 1st June 2020 (when 
English schools returned) respectively. These terms were interacted with time to parameterise 
the slope beyond initial lockdown and lockdown easing. Adjustment was made for weeks 
which included a bank holiday, Christmas 2019 (parameterised separately as this week 
includes two bank holidays) and seasonal variation (incorporated using Fourier 
terms)(Appendix page 2).(13) Newey-West errors were used to recognise auto-regressive 
errors and heteroscedasticity.  Model predictions are presented graphically alongside the 
observed weekly course/attendance numbers. Separate models were fitted to both the adjusted 
(recognising missing data) and observed data. Statistical significance was defined as p<0.05. 
The ITS model was used to predict the reduction in courses delivered between 23rd March 
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and 28th June 2020 based on data following adjustment for missing with confidence intervals 
defined based upon the linear model predictions.  
 
Analysis of the change in use of hypofractionation: 
Change in treatment fractionation was assessed for patients aged 18 years and older for 
specified diagnoses (see Appendix page 1). Radical treatments were grouped into categories 
based on the prescribed dose per fraction (less than 2Gy per fraction, standard fractionation 
(2-2·49Gy/fraction), mild-moderate hypofractionation (2.5-4·9Gy per fraction) and ultra-
hypofractionation (>=5Gy per fraction)). The proportion of activity delivered using each 
categorisation was assessed by diagnosis. Palliative treatments delivered to these diagnoses 
were separately grouped as single fraction, two to five fractions, six to ten fractions and 
greater than ten fractions, then analysed similarly.  
 
Based on the extensive changes observed in fractionation patterns delivered for breast cancer, 
these were investigated further using ITS analysis. This was conducted as detailed previously 
using a Poisson distribution to allow recognition of the small number of courses per week for 
some regimens.  
 
All statistical analyses were carried out using StataIC 64, version 16. Data are presented 
graphically using Stata1C 64, Tableau and Excel. 
 
No study specific funding was sought and no funding organisation had a role in study design, 
data collection, data analysis, data interpretation, or writing of the report. The corresponding 
author had full access to all of the data extracted from PHE and the final responsibility to 
submit for publication. 
 
RESULTS: 
The average weekly number of radiotherapy courses delivered across the English NHS in 
2019 was 2,570 (SD 246). This fell 502 (-19·9%) in April 2020 from 2,526 (SD 178·2) in 
April 2019 (Table 1 and Appendix page 2).  A fall of 151 (-6·2%) from 2,425 (SD 172·1) 
was observed in May and 307 (-11‧6%) from 2,633 (SD 59·6) in June 2020. In comparison, 
greater reductions, of 10,290 (-29.1%) from 35,332 (SD 2,543·8), 10,573 (-31.4%) from 
33,665 (SD 2776·1) and 11,380 (-31‧5%) from 36130 (SD 232·7), were observed for 
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treatment attendances (approximating to fractions) in April, May, and June 2020 respectively 
when compared with equivalent months in 2019.  
 
Substantial variation was seen across radiotherapy providers in both the direction and 
magnitude of change in average weekly courses, ranging from -53‧5% to +13·3% in April 
2020, -45‧7% - +15‧4% in May 2020 and -28‧7% to +31‧9% in June 2020 (see Appendix page 
8).  All regions of the country saw a fall in activity in April with subsequent recovery, though 
the extent of this varied (Appendix page 9).  
 
On ITS analyses lockdown was associated with a significant reduction in courses and 
treatment attendances (p<0.001 for all pandemic terms). Model outputs are presented in Fig.1 
and Appendix pages 4-5. Between 23rd March and 28th June a predicted 3,263 (95% CI 
2,936-3,590) fewer treatment courses and 119,050 (95%CI 112,632-125,470) fewer 
attendances were delivered in England than would have been expected had the pandemic not 
occurred. 
 
Changes in average weekly curative treatment courses and attendances for individual 
diagnoses, are provided in Table 2 and Appendix page 10. The largest reduction was 
observed in prostate cancer (in April, May and June 2020 falls of 266 (-77·0%) from 
346(SD43·3), 198 (-58‧0%) from 342(SD24·9) and 75 (-13‧7%) from 360(SD17·0) 
respectively were observed compared to the equivalent months in 2019) and non-melanoma 
skin cancer (NMSC; falling 58 (-72‧4%) from 80(SD16.2), 47 (-57‧8%) from 81(SD19·7) and 
26 (-28‧4%) from 90(SD16·5) for the same periods). Conversely, marked increases were seen 
in other diagnoses: bladder cancer courses increased 18 (64‧2%) from 27(SD5·1), 32 
(143‧3%) from 23(SD4·5) and 4 (17‧1%) from 24(SD2·1); oesophageal cancer (14 (41‧2%) 
from 32(SD9·6), 18 (71‧3%) from 25(SD3·2) and fell 1 (-3‧2%) from 29(SD3·0); and rectal 
cancer (increased 25 (36‧3%) from 69(SD10.9), 15 (22‧3%) from 65(SD9·2) and then fell 31 
(-43‧7%) from 72(SD10·4)) in April, May and June 2020 respectively.  
 
The average weekly number of treatment courses delivered to patients aged 70 years and over 
in April 2020 fell 403; (34‧4%) from 1,171 (SD 94‧4) in April 2019. A smaller reduction was 
seen in those under 70 (99 (-7.3%) from 1,355 (SD 91‧5) in April 2019. Of these, a weekly 
average of less than 12 courses was delivered to patients under the age of 18 throughout the 
study period. Given these small numbers, temporal changes over time were not assessed.  
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The differential impact of age was most marked in breast cancer (average weekly courses 
falling 59 (-32‧5%) from 182(SD25.1) in those aged 70 and over versus increasing 1 (0·3%) 
from 513(SD42‧0) in those under 70), and NMSC (57 (-71‧0%) from 80.2(SD14‧0) and 6 (-
52‧9%) from 12(SD4‧1) respectively)((Appendix page 12-14).  
 
In April 2019, 60.9% of curative courses delivered to patients of 18 years and over used a 
mild-moderately fractionated regimen (2·5-4·9 Gy per fraction). This fell to 38.9% in April 
2020 and remained low in May and June 2020 (39.9% and 43.4% respectively). In contrast, 
ultra-hypofractionation (>=5Gy per fraction) increased from 9·4% in April 2019 to 39.9%, 
40·0% and 34·0% in April, May and June 2020. Figure 2 and Appendix page 6 show these 
results for individual diagnoses.  
 
A major contributor to this was the increased use of 26Gy in 5 fractions for adjuvant breast 
cancer treatment. Whilst in April 2019 0‧2% of courses were delivered using this regimen, 
this increased to 60·6% in April 2020. Conversely the use of 40Gy in 15 fractions fell from 
91‧5% to 33‧0% on the same comparison. ITS regression confirmed the statistical 
significance of these changes (Figure 3 and Appendix page 7). 
 
The proportion of palliative treatment courses delivered using a single fraction rose from a an 
average weekly of 223 (39·3%) of 568(SD36·8) in April 2019 to 233 (50‧3%) of 
463(SD62·3) in April 2020, with a corresponding fall in treatments delivered using more than 




We demonstrate that the number of patients receiving radiotherapy in the English NHS fell 
significantly during the first wave of the COVID-19 pandemic. When compared to a year 
previously, a 20% reduction in radiotherapy courses was seen immediately after the UK 
national lockdown in April 2020. Recovery was not complete by June 2020 (12% reduction), 
despite the easing of lockdown and decrease in number of NHS inpatients with COVID-19. 
We project that compared to the same period a year previously (23rd March – 28th June 2020), 
3,263 fewer treatment courses were delivered with 119,050 fewer treatment attendances 
across the English NHS. The disproportionately greater fall in treatment attendances reflects 
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a rapid increase in the use of hypofractionated treatment regimens across a number of tumour 
sites. 
 
These analyses are based on a comprehensive national dataset. However, the reduction in 
activity that we report compares favourably to the more limited surveys of radiation oncology 
departments undertaken following the first pandemic peak in both the United States of 
America (USA) and Europe.(7,8) An approximate 25% reduction in patient volume was for 
instance reported for centres in Europe, including the UK, with patient volume in the USA 
predicted to be a third lower. In contrast, at 8% the reported median reduction in patient 
volume in Latin America is far more modest than observed here.(6)  
 
Beyond overall changes in radiotherapy activity, we also highlight how these changes varied 
by age group and diagnosis. At the onset of the pandemic, a number of professional bodies 
issued guidance for safely maintaining radiotherapy services.(4,5) A key concern at the time 
related to the potential for hospitals to act as a reservoir for SARS-CoV-2,(14) and for a 
potentially heightened risk from COVID-19 for patients with cancer, particularly for those 
aged 70 years and older.(11) Reflecting this, many guidelines advocated the deferral of 
treatment where it was safe to do so, or where the potential risks of treatment outweighed the 
benefits.  
 
We demonstrate that treatment courses fell by a much a greater degree in patients aged 70 
years and older. This may partly be a consequence of decisions made by clinicians and 
patients to defer treatment in this higher-risk group. It may also in part reflect the age profile 
of prostate cancer and NMSC, where falls greater than anticipated from European surveys 
were observed. In prostate cancer, randomised evidence supports delay of up to six months 
using androgen deprivation therapy, or even for active surveillance in low-risk disease.(15,16) 
The extent to which evidence supports treatment delays in NMSC is less well defined, 
although for small basal cell carcinomas delay is unlikely to change the likelihood of cure.(17) 
Additionally, a differential effect was seen in breast cancer, potentially reflecting altered 
clinical decision-making based on an assessment of risk and informed by the results of the 
PRIME-II trial.(18)  Similarly, specific concerns for adverse COVID-19 outcomes in patients 
with lung cancer may have contributed to the reduction in 2Gy per fraction treatments (often 




In contrast, a rise in curative courses was observed for rectal, bladder, oesophageal and head 
and neck cancers during April and May 2020; cancers in which disease biology precludes 
significant treatment delays. The increase observed here may reflect the use of radiotherapy 
as an alternative definitive treatment approach to surgery.  A number of modelling studies 
have estimated large numbers of excess deaths due to limitations to surgical services.(19,20) 
However, these studies have not taken into account the use of radiotherapy in place of 
surgery as appears to be demonstrated here. Equally, whilst equipoise exists between 
radiotherapy and surgery for the treatment of bladder cancer and oesophageal squamous cell 
carcinoma, surgery is superior in oesophageal adenocarcinoma.(21,22) For rectal cancer, 
radiotherapy offers a mechanism to support delayed surgery with the potential for a 
substantial minority to avoid resection entirely. One immediate consequence of this shift in 
treatment patterns should be an urgent review of post-treatment surveillance protocols to 
ensure that patients who received an alternative treatment approach, and for whom cancer 
recurs can, where appropriate, be swiftly identified and referred for salvage resection. In the 
long-term, analysis of the outcomes of those who have undergone radiotherapy in place of 
surgery, for reasons unrelated to their individual baseline condition, may provide valuable 
comparative data in settings where randomisation between surgery and radiotherapy has 
historically been challenging.(21)   
  
In line with guidance advocating reductions in hospital visits, treatment attendances fell 
significantly post-lockdown as a consequence of the wider use of hypofractionated 
radiotherapy. Most strikingly, the results of the FAST-Forward trial were incorporated into 
national guidelines supporting rapid and widespread adoption of a 26Gy in five fractions 
regimen in place of the previous 40Gy in 15 fractions standard for adjuvant breast cancer 
radiotherapy.(23,24) In this context, the decision in March 2020 to move away from a per-
attendance tariff for national radiotherapy commissioning is likely to have supported 
providers in rapidly adopting this new evidence base.(1) In addition, as a UK-wide study the 
experience of delivering these quality-assured hypofractionated regimens within a trial setting 
will likely have aided its rapid implementation.(23) These changes demonstrate that at least for 
some indications, the pandemic has beneficially catalysed the adoption of a new evidence 
base. 
 
An increase in hypofractionation was also seen for palliative treatments, with half of these 
delivered as a single fraction in April 2020. This change is appropriate and in keeping with 
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evidence for most palliative indications. However, the concomitant reduction in the number 
of palliative treatment courses is concerning given the role of these treatments in improving 
quality of life for patients with localised symptoms due to advanced incurable cancer.(25) 
 
Finally, in keeping with centres ‘catching up’ on deferred treatments, prostate and NMSC 
treatments were returning to baseline in June 2020. Across a range of other diagnoses, despite 
lesser falls during lockdown, a reduction in activity was observed in June compared to the 
previous year. For some diagnoses (e.g. cervix cancer) the temporary reduction/cessation of 
screening programmes may have played a role. However, NHS waiting time data demonstrate 
that in June 2020, referrals for possible symptomatic cancer remained 21% below those in 
June 2019. New diagnoses were suppressed by 26%, which is likely a key contributor to the 
ongoing suppression in radiotherapy activity through June 2020.(26) Consistent with this,  
there was limited change in compliance with the 31-day treatment targets in radiotherapy, 
which remained above 95% throughout the study period.(27) The time between diagnosis and 
commencing treatment may have limited the impact of the pandemic in May (compared to 
April and June), as previously diagnosed patients began their treatment. These results 
reinforce concerns about the impact of the COVID-19 pandemic on cancer diagnostic 
pathways and, in turn, outcomes.(28,29) This will require examination in future, once complete 
cancer registration data are available. 
 
This is the first comprehensive national analysis of changes in cancer treatment provision 
during the first wave of the COVID-19 pandemic. Nevertheless, it does have limitations. Data 
were only available for England and a lag in data collection and availability (of 
approximately 2-3 months) means more contemporaneous data are not available, so that 
longer-term changes in radiotherapy activity beyond the first wave of the pandemic cannot 
yet be seen. In addition, data were missing from four centres which had not completed their 
activity submission in June. However, having adjusted for this within our analyses it is 
unlikely to significantly impact on the conclusions reached. A small number of private 
providers deliver radiotherapy in England. Data from these providers are not routinely 
collected, so we cannot comment on the role of the private sector. Due to the limitations of 
and longitudinal changes in COVID-19 testing in England it is extremely challenging to 
interpret the relationship between regional COVID-19 prevalence and radiotherapy delivery 
and as such this was not attempted. Finally, whilst the RTDS provides robust data on the 
changes in courses and attendances for radiotherapy, it does not provide data on why these 
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changes were made. Whilst assumptions can be made for the population as a whole, the data 
cannot provide definitive information on an individual patient level. Data relating to 
individual patient treatment decisions made during the COVID-19 pandemic will be collated 
by the National Cancer Research Institute Clinical and Translational Radiotherapy Research 
Working Group (NCRI CTRad) COVID RT initiative, and will be linked with other national 
datasets to determine the impact on patient outcomes.(30)  
 
Conclusions: 
Radiotherapy activity in the English NHS fell significantly during the first wave of the 
COVID-19 pandemic. This occurred predominantly in cancers where treatment may be safely 
delayed and through the use of hypofractionation. In contrast, increased activity in specific 
diagnoses suggests that radiotherapy was used to compensate for reduced surgical activity. 
Overall, the impact on cancer outcomes of changes in radiotherapy activity during the first 
pandemic peak is likely to be modest, and an increase in radiotherapy utilisation may have 
helped to mitigate against the loss of surgical capacity. However, the continued suppression 
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Table 1. Average weekly courses and attendances in the months following lockdown.  Average weekly numbers 
are displayed with % change compared to corresponding month of 2019 displayed below. “Other” intent reflects 
those where the intent was not specified, numbers in this group dropped steeply in 2019 with improvements to 
data collection, although given their low frequency this change is unlikely to have had a significant impact upon 
























Total Observed 2631 2449 2024 2274 2130 36121 34716 25042 23092 22631 
Adjusted 2659 2449 2024 2274 2326 36489 34716 25042 23092 24750 
Std dev. 107.4 238.8 226.0 246.1 59.1 514.2 2459.9 1016.9 1664.9 594.4 
% change  -2.9 -7.8 -19.9 -6.2 -11.6 -2.4 -8.5 -29.1 -31.4 -31.5 
Palliative Observed 847 827 653 789 788 3593 3380 2270 2623 2771 
Adjusted 855 827 653 789 861 3629 3380 2270 2623 3030 
Std dev. 32.9 59.9 75.1 112.7 65.0 161.6 415.2 228.2 355.1 240.8 
% change  1.0 -1.8 -20.1 -1.5 -5.3 0.7 -7.0 -35.7 -20.9 -20.4 
Radical Observed 1774 1614 1362 1474 1332 32426 31227 22684 20376 19792 
Adjusted 1793 1614 1362 1474 1454 32756 31227 22684 20376 21645 
Std dev. 83.0 205.5 151.9 136.9 15.7 569.7 2053.7 949.9 1354.9 364.0 
% change  -3.1 -9.3 -19.4 -8.7 -15.2 -2.2 -8.2 -28.3 -32.6 -32.9 
Other Observed 11 9 9 10 10 103 108 88 93 68 
Adjusted 11 9 9 10 11 104 108 88 93 75 
Std dev. 5.4 3.3 3.8 1.0 2.0 14.1 8.1 11.4 15.0 13.8 
% change  -74.3 -74.5 -54.4 2.5 36.5 -62.9 -61.6 -50.2 -26.2 -16.4 
Female 
<70 
Observed 848 829 797 839 718 12196 11691 8974 8382 7459 
Adjusted 857 829 797 839 784 12320 11691 8974 8382 8157 
Std dev. 47.2 49.8 99.4 100.7 19.1 142.5 516.4 400.2 743.1 229.1 
% change  -2.6 -2.8 -2.2 5.3 -8.2 3.0 -7.3 -23.4 -25.7 -33.6 
Female 
≥70 
Observed 487 471 339 419 349 5464 5241 3526 3347 3100 
Adjusted 492 471 339 419 381 5520 5241 3526 3347 3390 
Std dev. 30.6 48.4 21.3 66.5 5.3 106.7 443.0 233.4 362.0 136.2 
% change  -2.3 -1.8 -25.8 -2.1 -18.9 -2.9 -6.9 -31.9 -32.6 -36.1 
Male <70 Observed 584 518 459 508 488 9159 8905 6885 6560 6590 
Adjusted 590 518 459 508 533 9252 8905 6885 6560 7207 
Std dev. 19.8 49.4 73.5 38.9 26.7 283.8 723.2 227.4 345.9 362.2 
% change  0.3 -10.0 -15.1 -2.7 -6.7 -2.8 -6.8 -22.8 -23.0 -19.2 
Male ≥70 Observed 713 631 429 508 575 9302 8878 5657 4803 5483 
Adjusted 720 631 429 508 628 9397 8878 5657 4803 5996 
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Std dev. 44.6 126.8 42.0 55.8 61.6 125.0 819.7 365.2 285.5 584.9 







Table 2. Average weekly number of radical episodes and attendances by month for individual diagnoses. 
Observed weekly average, weekly average adjusted for missing data and percentage change compared to the 
equivalent month in 2019 based on adjusted data presented. Where smaller diagnoses are considered the 

























Anal Observed 22 25 23 20 11 615 614 635 598 382 
Adjusted 22 25 23 20 12 622 614 635 598 418 
Std dev 5.8 5.4 6.6 3.9 0.5 45.3 25.3 27.0 48.8 63.5 
% change -4.4 21.5 9.7 2.6 -48.9 11.2 8.7 16.7 12.5 -27.2 
Bladder Observed 20 28 45 55 26 370 521 730 992 674 
Adjusted 20 28 45 55 28 373 521 730 992 737 
Std dev 4.8 3.4 4.8 11.1 6.2 29.4 61.3 124.7 84.9 132.8 
% change -7.3 -1.4 64.2 143.3 17.1 -27.9 3.7 37.4 87.0 48.8 
Brain Observed 58 51 43 42 41 1325 1145 948 845 817 
Adjusted 58 51 43 42 45 1338 1145 948 845 893 
Std dev 8.8 7.2 7.4 4.4 6.7 75.5 67.4 54.8 80.1 65.7 
% change -10.6 -24.7 -19.9 -28.4 -22.6 10.6 -20.0 -26.7 -25.1 -33.0 
Breast Observed 634 597 570 618 493 9617 9289 6036 5400 4828 
Adjusted 640 597 570 618 539 9715 9289 6036 5400 5279 
Std dev 41.4 42.5 91.8 90.3 35.0 361.8 556.3 347.1 639.7 325.9 
% change 1.3 -4.5 -4.5 6.6 -12.5 2.8 -5.7 -34.8 -39.9 -45.4 
Cervix Observed 21 21 22 17 13 520 471 563 464 360 
Adjusted 21 21 22 17 14 525 471 563 464 394 
Std dev 4.2 7.3 4.8 4.7 3.9 47.9 29.6 15.3 49.1 18.1 
% change -10.9 6.3 0.7 -37.7 -32.7 -9.9 -16.6 12.2 -19.3 -37.6 
Head and 
Neck 
Observed 122 120 132 116 80 3249 3337 3415 3319 2467 
Adjusted 124 120 132 116 87 3282 3337 3415 3319 2698 
Std dev 13.7 15.8 23.5 23.0 3.2 98.1 62.4 147.3 204.7 249.4 
% change -0.2 4.2 9.7 4.0 -25.6 -6.6 -2.9 5.1 3.4 -18.8 
Lung Observed 135 140 139 147 102 1955 2089 1893 1884 1350 
Adjusted 136 140 139 147 111 1974 2089 1893 1884 1476 
Std dev 7.0 13.1 13.3 21.7 19.1 76.6 72.2 79.8 154.6 158.4 
% change 6.8 8.5 -1.9 10.8 -11.5 8.2 9.0 -5.8 -0.1 -21.5 
Lymphoma 
 
Observed 55 52 40 49 45 760 706 523 497 556 
Adjusted 56 52 40 49 49 768 706 523 497 608 
Std dev 5.0 9.1 7.0 8.7 3.9 31.4 55.9 48.0 83.9 5.2 
% change 5.9 -5.5 -19.2 23.1 -1.7 12.2 -10.8 -25.1 -14.2 -7.9 
Oesophageal Observed 24 30 46 43 25 519 621 735 1110 658 
Adjusted 25 30 46 43 28 524 621 735 1110 720 
Std dev 1.7 7.6 17.0 11.1 1.9 18.7 17.9 142.0 80.9 108.9 
% change -14.8 1.9 41.2 71.3 -3.2 -9.1 -7.3 9.5 79.8 18.8 
Other dx 
 
Observed 148 124 107 113 115 2642 2284 1858 1837 1886 
Adjusted 149 124 107 113 125 2668 2284 1858 1837 2062 
Std dev 14.3 7.9 19.1 11.5 10.2 92.6 221.3 96.3 92.2 117.4 
% change 2.4 -8.0 -17.8 2.3 -3.6 9.5 -11.0 -19.2 -15.9 -10.2 
Prostate Observed 372 285 80 144 285 8471 7958 3706 2174 4595 
Adjusted 375 285 80 144 311 8557 7958 3706 2174 5025 
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Std dev 30.1 114.8 10.5 53.7 44.5 248.7 976.5 852.3 223.6 1124.5 
% change -10.9 -25.3 -77.0 -58.0 -13.7 -12.4 -14.3 -55.7 -72.5 -39.7 
Rectal Observed 72 76 94 80 37 1435 1445 1252 907 602 
Adjusted 73 76 94 80 41 1449 1445 1252 907 658 
Std dev 6.7 8.8 24.1 14.4 8.6 29.9 68.0 81.8 170.7 40.6 
% change -5.2 -5.7 36.3 22.3 -43.7 9.5 0.2 -8.6 -29.3 -55.8 
Skin Observed 94 65 22 34 59 949 747 389 352 618 
Adjusted 94 65 22 34 64 959 747 389 352 676 
Std dev 18.0 23.9 2.7 8.3 6.1 84.0 132.9 55.7 59.4 104.3 






Figure 1a) courses and b) attendances of radiotherapy delivered within the English NHS over the year preceding 
and period following UK lockdown for the COVID-19 pandemic. Grey dots represent the observed weekly 
numbers and orange dots weekly numbers after adjustment for missing data. The grey line shows the model 
predictions of weekly courses from the interrupted time-series model fitted to the adjusted data, the blue line the 
predicted number of courses and attendances in the absence of the pandemic and the orange line the predicted 









  Figure 2. Bubble plot illustrating the change in fractionation patterns delivered for radical treatment to a range 
of individual diagnoses over time in descending order of total number of courses. The proportion of treatment 
delivered using a given fractionation category is displayed on the y-axis of each panel and the total number of 
treatment courses in the period on the x-axis. The size of the bubble reflects the number of treatments delivered 






Figure 3. Change in fractionation patterns delivered for breast cancer across the English NHS prior to and 
following lockdown. Model predictions (lines) of the use of differing regimens for the adjuvant treatment of 
breast cancer with observed weekly courses (dots). Grey = 40Gy in 15 fractions, Orange = 26Gy in five 

























1.  Stevens S, Pritchard A. Next steps on NHS repsonse to COVID-19 [Internet]. 2020 [cited 
2020 Sep 28]. Available from: https://www.england.nhs.uk/coronavirus/wp-
content/uploads/sites/52/2020/03/20200317-NHS-COVID-letter-FINAL.pdf 
2.  In WHO global pulse survey, 90% of countries report disruptions to essential health 
services since COVID-19 pandemic [Internet]. [cited 2020 Oct 19]. Available from: 
https://www.who.int/news/item/31-08-2020-in-who-global-pulse-survey-90-of-countries-
report-disruptions-to-essential-health-services-since-covid-19-pandemic 
3.  Borras JM, Lievens Y, Dunscombe P, Coffey M, Malicki J, Corral J, et al. The optimal 
utilization proportion of external beam radiotherapy in European countries: An ESTRO-
HERO analysis. Radiother Oncol. 2015 Jul 1;116(1):38–44.  
4.  Overview | COVID-19 rapid guideline: delivery of radiotherapy | Guidance | NICE 
[Internet]. NICE; [cited 2020 Jun 25]. Available from: 
https://www.nice.org.uk/guidance/NG162 
5.  Royal College of Radiologists. Coronavirus (COVID-19): Cancer treatment documents. 
https://www.rcr.ac.uk/college/coronavirus-covid-19-what-rcr-doing/clinical-
information/coronavirus-covid-19-cancer.  
6.  Martinez D, Sarria GJ, Wakefield D, Flores C, Malhotra S, Li B, et al. COVID’s Impact 
on Radiation Oncology: A Latin American Survey Study. Int J Radiat Oncol. 2020 
Oct;108(2):374–8.  
7.  ASTRO. COVID-19’s Impact on Radiation Oncology - Initial results of a Nationawide 
Physician Survey, 5/20/20 [Internet]. 2020 May [cited 2020 Nov 9]. Available from: 
https://www.astro.org/ASTRO/media/ASTRO/News%20and%20Publications/PDFs/AST
ROCOVID19Survey1-ExecSummary.pdf 
8.  Slotman BJ, Lievens Y, Poortmans P, Cremades V, Eichler T, Wakefield DV, et al. 
Effect of COVID-19 pandemic on practice in European radiation oncology centers. 
Radiother Oncol. 2020 Sep;150:40–2.  
9.  National Radiotherapy Dataset (RTDS) [Internet]. [cited 2020 Sep 28]. Available from: 
http://www.ncin.org.uk/collecting_and_using_data/rtds 
10.  ICD-10 2010 [Internet]. [cited 2017 Feb 10]. Available from: 
http://apps.who.int/classifications/icd10/browse/2010/en#/II 
11.  Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors 
associated with COVID-19-related death using OpenSAFELY. Nature. 2020 
Aug;584(7821):430–6.  
12.  Who’s at higher risk from coronavirus (COVID-19) [Internet]. nhs.uk. 2020 [cited 2020 
Oct 12]. Available from: https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-
higher-risk/whos-at-higher-risk-from-coronavirus/ 
13.  Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation 
of public health interventions: a tutorial. Int J Epidemiol. 2017 Feb;46(1):348–55.  
22 
 
14.  Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With 
Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020 Jul 1;6(7):1108.  
15.  Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, et al. Prostate 
Cancer Radiation Therapy Recommendations in Response to COVID-19. Adv Radiat 
Oncol [Internet]. 2020 Apr 1 [cited 2020 Jun 29]; Available from: 
http://www.sciencedirect.com/science/article/pii/S2452109420300610 
16.  Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, et al. Duration 
of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation 
Therapy Oncology Group Randomized Clinical Trial 9910. J Clin Oncol. 2015 Feb 
1;33(4):332–9.  
17.  Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and 
squamous cell carcinomas of the skin. Int J Radiat Oncol. 2004 Oct;60(2):406–11.  
18.  Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery 
with or without irradiation in women aged 65 years or older with early breast cancer 
(PRIME II): a randomised controlled trial. Lancet Oncol. 2015 Mar 1;16(3):266–73.  
19.  Sud A, Jones ME, Broggio J, Loveday C, Torr B, Garrett A, et al. Collateral damage: the 
impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol. 2020 
Aug 1;31(8):1065–74.  
20.  Lai AG, Pasea L, Banerjee A, Denaxas S, Katsoulis M, Chang WH, et al. Estimating 
excess mortality in people with cancer and multimorbidity in the COVID-19 emergency. 
medRxiv. 2020 Jun 1;2020.05.27.20083287.  
21.  Huddart RA, Birtle A, Maynard L, Beresford M, Blazeby J, Donovan J, et al. Clinical and 
patient‐reported outcomes of SPARE – a randomised feasibility study of selective 
bladder preservation versus radical cystectomy. Bju Int. 2017 Nov;120(5):639–50.  
22.  Crosby T, Hurt CN, Falk S, Gollins S, Staffurth J, Ray R, et al. Long-term results and 
recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive 
chemoradiotherapy +/ − cetuximab in oesophageal cancer. Br J Cancer. 2017 
Mar;116(6):709–16.  
23.  Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, 
et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 
5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, 
randomised, phase 3 trial. Lancet Lond Engl. 2020 May 23;395(10237):1613–26.  
24.  Coles C. Guidelines on radiation therapy for breast cancer during the COVID-19 
pandemic. [cited 2020 Nov 6]; Available from: 
https://www.rcr.ac.uk/sites/default/files/breast-cancer-treatment-covid19.pdf 
25.  Spencer K, Parrish R, Barton R, Henry A. Palliative radiotherapy. BMJ. 2018 Mar 
23;k821.  





27.  NHS England. Statistics » Cancer Waiting Times [Internet]. [cited 2020 Nov 9]. 
Available from: https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-
waiting-times/ 
28.  Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of 
the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a 
national, population-based, modelling study. Lancet Oncol. 2020 Aug;21(8):1023–34.  
29.  Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. Effect of delays in the 2-
week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in 
the UK: a modelling study. Lancet Oncol. 2020 Aug;21(8):1035–44.  
30.  Lewis PJ, Morris EJA, Chan CSK, Darley K, Sebag-Montefiore D, Evans M. COVID RT 
– Assessing the Impact of COVID-19 on Radiotherapy in the UK. A National Cancer 
Research Institute Clinical and Translational Radiotherapy Research Working Group 
Initiative in Partnership with the Royal College of Radiologists, the Society of 
Radiographers and the Institute of Physics and Engineering in Medicine. Clin Oncol R 
Coll Radiol G B [Internet]. 2020 Sep 2 [cited 2020 Oct 8]; Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467021/ 
 
 
 
 
